Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 26, 2020; 8(16): 3458-3464
Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3458
Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis
Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan
Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, Dongguan 523326, Guangdong Province, China
Author contributions: Chen JM and Zhong YT designed this retrospective study; Chen JM wrote this paper; Tu C was responsible for sorting the data.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Dongguan Songshan Lake Central Hospital.
Informed consent statement: Informed consent was obtained from the patients.
Conflict-of-interest statement: Dr. Lan J reports a grant from Dongguan Social Science and Technology Development Project (No. 2015108101025) during the conduct of the study. Other authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jun Lan, MD, Chief Physician, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, No. 1 Xianglong Road, Dongguan 523326, Guangdong Province, China. dglanjun@163.com
Received: April 9, 2020
Peer-review started: April 9, 2020
First decision: April 29, 2020
Revised: May 12, 2020
Accepted: July 14, 2020
Article in press: July 14, 2020
Published online: August 26, 2020
Processing time: 137 Days and 23.8 Hours
Abstract
BACKGROUND

The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias.

AIM

To investigate the levels and significance of serum fibroblast growth factor 23 (FGF-23) and miR-208b in patients with atrial fibrillation and their relationship with prognosis.

METHODS

From May 2018 to October 2019, 240 patients with atrial fibrillation were selected as an observation group, including 134 with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation; 150 patients with healthy sinus rhythm were selected as a control group. The serum levels of FGF-23 and miR-208b in the two groups were measured. In the observation group, cardiac parameters were determined by echocardiography.

RESULTS

The serum levels of FGF-23 and miR-208b in the observation group were 210.20 ± 89.60 ng/mL and 5.30 ± 1.22 ng/mL, which were significantly higher than the corresponding values in the control group (P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were 234.22 ± 70.05 ng/mL and 5.83 ± 1.00 ng/mL, which were significantly higher than the corresponding values in patients with paroxysmal atrial fibrillation (P < 0.05). The left atrial dimension (LAD) of patients with persistent atrial fibrillation was 38.81 ± 5.11 mm, which was significantly higher than that of patients with paroxysmal atrial fibrillation (P > 0.05). The serum levels of FGF-23 and miR-208b were positively correlated with the LAD (r = 0.411 and 0.382, P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, which were significantly higher than the corresponding values in patients without a MACE (P < 0.05).

CONCLUSION

The serum levels of FGF-23 and miR-208b are increased in patients with atrial fibrillation and are related to the type of disease, cardiac parameters, and prognosis.

Keywords: Fibroblast growth factor-23; MiR-208b; Atrial fibrillation; Prognosis

Core tip: In this study, the authors investigated the levels and significance of serum fibroblast growth factor 23 and miR-208b in patients with atrial fibrillation and their relationship with prognosis.